Compliance Certificate For The Year Ended March 31, 2017
Compliance Certificate under Regulation 7(3) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 for the year ended March 31, 2017 Statement Of Investor Complaints For The Fourth Quarter Ended March 31, 2017
Statement of Investor Complaints under Regulation 7(3) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 for the fourth quarter ended March 31, 2017 Updates
Change in Email Address and Telephone and Fax Nos under Corporate Information displayed under Registered Office Section of the Company on BSE Website Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Reliance Nippon Life Asset Management Ltd Standalone Financial Results, Limited Review Report for December 31, 2016
Abbott India Ltd has informed BSE about : 1. Standalone Financial Results for the period ended December 31, 20162. Standalone Limited Review for the period ended December 31, 2016 Board Meeting Intimation for Results & Closure of Trading Window
Abbott India Ltd has informed BSE that a Meeting of the Board of Directors of the Company is scheduled to be held on February 06, 2017, inter alia, to consider and approve the text of Unaudited Financial Results of the Company for the third quarter and nine months ended on December 31, 2016.Further, in terms of Abbott India Code of Internal Procedures and Conduct for Regulating, Monitoring and Reporting of Trading by Insiders, the Trading... Abbott to make India hub of global research and development for branded generics
Abbott, the largest drug company operating in India in terms of domestic market share, following the acquisition of Piramal Healthcare's formulation division in 2010, is setting up an Innovation and Design Centre in Mumbai, which will take off next year. Schedule of meeting with analysts/ Institutional Investors
Abbott India Ltd has informed BSE regarding Schedule of meeting with analysts/ Institutional Investors. Statement of Investor Complaint under Reg. 13(3) of SEBI (LODR) Regulations, 2015 for Quarter ended December 31, 2016
Abbott India Ltd has informed BSE regarding Quarterly Statement on Investor Complaints / Grievances Redressal Mechanism for the Quarter ended December 31, 2016, under Regulation 13(3) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Shareholding for the Period Ended December 31, 2016
Abbott India Ltd has submitted to BSE the Shareholding Pattern for the Period Ended December 31, 2016. For more details, kindly Click here